Type II diabetes mellitus
Conditions
Interventions
Oral sitagliptin administration (50 mg) once daily before breakfast
Sponsors
Nippon Medical School Department of Medicine Division of Cardiology, Hepatology,Geriatrics and Integrated Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Age more than 20 years 2) Outpatients 3) Inadequate glucose control even after dietary and exercise therapies for more than 8 weeks 4) No previous administration of pioglitazone as an oral hypoglycemic drug 5) 6.1% more than fasting HbA1c under 10% 6) Fasting blood glucose less than 270 mg/dl 7) Patients who themselves can voluntarily provide written consent to participate in this study, and can also follow the study protocol
Exclusion criteria
Exclusion criteria: 1) Type I diabetes mellitus 2) Patients receiving insulin therapy 3) Severe renal dysfunction requiring hemodialysis or peritoneal dialysis 4) Severe hepatopathy/nephropathy or heart disease that may affect the evaluation of drug safety 5) Patients who are deemed to be inappropriate by the investigator or sub-investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Flow mediated dilation (FMD) | — |
Secondary
| Measure | Time frame |
|---|---|
| HbA1c, fasting blood glucose, autonomic nerve function | — |
Countries
Japan
Outcome results
None listed